Browse VTN

Summary
SymbolVTN
Namevitronectin
Aliases VN; serum spreading factor; somatomedin B; complement S-protein; vitronectin (serum spreading factor, somato ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space.
Domain PF00045 Hemopexin
PF01033 Somatomedin B domain
Function

Vitronectin is a cell adhesion and spreading factor found in serum and tissues. Vitronectin interact with glycosaminoglycans and proteoglycans. Is recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway.; FUNCTION: Somatomedin-B is a growth hormone-dependent serum factor with protease-inhibiting activity.

> Gene Ontology
 
Biological Process GO:0001704 formation of primary germ layer
GO:0001706 endoderm formation
GO:0001889 liver development
GO:0002526 acute inflammatory response
GO:0002673 regulation of acute inflammatory response
GO:0002697 regulation of immune effector process
GO:0002920 regulation of humoral immune response
GO:0006898 receptor-mediated endocytosis
GO:0006956 complement activation
GO:0006959 humoral immune response
GO:0007160 cell-matrix adhesion
GO:0007369 gastrulation
GO:0007492 endoderm development
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0010001 glial cell differentiation
GO:0010466 negative regulation of peptidase activity
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0010951 negative regulation of endopeptidase activity
GO:0014812 muscle cell migration
GO:0014909 smooth muscle cell migration
GO:0014910 regulation of smooth muscle cell migration
GO:0014911 positive regulation of smooth muscle cell migration
GO:0016485 protein processing
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0030100 regulation of endocytosis
GO:0030193 regulation of blood coagulation
GO:0030195 negative regulation of blood coagulation
GO:0030198 extracellular matrix organization
GO:0030335 positive regulation of cell migration
GO:0030449 regulation of complement activation
GO:0030947 regulation of vascular endothelial growth factor receptor signaling pathway
GO:0030949 positive regulation of vascular endothelial growth factor receptor signaling pathway
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0031589 cell-substrate adhesion
GO:0032092 positive regulation of protein binding
GO:0032102 negative regulation of response to external stimulus
GO:0033627 cell adhesion mediated by integrin
GO:0035987 endodermal cell differentiation
GO:0040017 positive regulation of locomotion
GO:0042063 gliogenesis
GO:0043062 extracellular structure organization
GO:0043393 regulation of protein binding
GO:0045785 positive regulation of cell adhesion
GO:0045807 positive regulation of endocytosis
GO:0045861 negative regulation of proteolysis
GO:0048010 vascular endothelial growth factor receptor signaling pathway
GO:0048259 regulation of receptor-mediated endocytosis
GO:0048260 positive regulation of receptor-mediated endocytosis
GO:0048709 oligodendrocyte differentiation
GO:0048732 gland development
GO:0050727 regulation of inflammatory response
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050819 negative regulation of coagulation
GO:0050878 regulation of body fluid levels
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0051258 protein polymerization
GO:0051272 positive regulation of cellular component movement
GO:0051346 negative regulation of hydrolase activity
GO:0051604 protein maturation
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0060627 regulation of vesicle-mediated transport
GO:0061008 hepaticobiliary system development
GO:0061041 regulation of wound healing
GO:0061045 negative regulation of wound healing
GO:0061302 smooth muscle cell-matrix adhesion
GO:0070613 regulation of protein processing
GO:0072376 protein activation cascade
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090303 positive regulation of wound healing
GO:0097421 liver regeneration
GO:1900046 regulation of hemostasis
GO:1900047 negative regulation of hemostasis
GO:1903034 regulation of response to wounding
GO:1903035 negative regulation of response to wounding
GO:1903036 positive regulation of response to wounding
GO:1903317 regulation of protein maturation
GO:2000147 positive regulation of cell motility
GO:2000257 regulation of protein activation cascade
Molecular Function GO:0001871 pattern binding
GO:0005044 scavenger receptor activity
GO:0005178 integrin binding
GO:0005518 collagen binding
GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0030246 carbohydrate binding
GO:0030247 polysaccharide binding
GO:0038024 cargo receptor activity
GO:0050839 cell adhesion molecule binding
GO:0050840 extracellular matrix binding
GO:1901681 sulfur compound binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0005788 endoplasmic reticulum lumen
GO:0005791 rough endoplasmic reticulum
GO:0005796 Golgi lumen
GO:0044420 extracellular matrix component
GO:0048237 rough endoplasmic reticulum lumen
GO:0071062 alphav-beta3 integrin-vitronectin complex
GO:0072562 blood microparticle
> KEGG and Reactome Pathway
 
KEGG hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction
hsa04610 Complement and coagulation cascades
Reactome R-HSA-166658: Complement cascade
R-HSA-3000178: ECM proteoglycans
R-HSA-1566948: Elastic fibre formation
R-HSA-1474244: Extracellular matrix organization
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-216083: Integrin cell surface interactions
R-HSA-2129379: Molecules associated with elastic fibres
R-HSA-3000171: Non-integrin membrane-ECM interactions
R-HSA-977606: Regulation of Complement cascade
R-HSA-3000170: Syndecan interactions
Summary
SymbolVTN
Namevitronectin
Aliases VN; serum spreading factor; somatomedin B; complement S-protein; vitronectin (serum spreading factor, somato ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between VTN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolVTN
Namevitronectin
Aliases VN; serum spreading factor; somatomedin B; complement S-protein; vitronectin (serum spreading factor, somato ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of VTN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolVTN
Namevitronectin
Aliases VN; serum spreading factor; somatomedin B; complement S-protein; vitronectin (serum spreading factor, somato ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of VTN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.7270.0399
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.0540.467
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)872.2250.0554
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3690.321
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3950.816
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3330.879
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.2070.172
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1110.372
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.970.458
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7250.728
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.6150.319
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.150.649
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of VTN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolVTN
Namevitronectin
Aliases VN; serum spreading factor; somatomedin B; complement S-protein; vitronectin (serum spreading factor, somato ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of VTN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolVTN
Namevitronectin
Aliases VN; serum spreading factor; somatomedin B; complement S-protein; vitronectin (serum spreading factor, somato ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of VTN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by VTN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolVTN
Namevitronectin
Aliases VN; serum spreading factor; somatomedin B; complement S-protein; vitronectin (serum spreading factor, somato ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of VTN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolVTN
Namevitronectin
Aliases VN; serum spreading factor; somatomedin B; complement S-protein; vitronectin (serum spreading factor, somato ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of VTN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolVTN
Namevitronectin
Aliases VN; serum spreading factor; somatomedin B; complement S-protein; vitronectin (serum spreading factor, somato ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between VTN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolVTN
Namevitronectin
Aliases VN; serum spreading factor; somatomedin B; complement S-protein; vitronectin (serum spreading factor, somato ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting VTN collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting VTN.
ID Name Drug Type Targets #Targets
DB00054AbciximabBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......14
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141